Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has commenced its Phase 2a clinical trial for ATI-2138, an innovative oral covalent ...

But people with eczema know another possible explanation for their tell-tale flush: Atopic dermatitis on the face. Here's ...

Aclaris Therapeutics has dosed the first subject in the Phase IIa clinical trial of ATI-2138 to treat moderate to severe ...

Each installment will delve into another aspect of atopic dermatitis, including signs and symptoms, causes and triggers, genetic factors, related conditions, treatment options, coping strategies ...

It is not known if Adbry is a safe or effective treatment in children younger than 12. How Was Adbry Studied for Treating Atopic Dermatitis? Three clinical studies called ECZTRA 1, 2 ...

If your skin has started to resemble fish scales consult a doctor to understand its causes Here are some possible causes to ...

The Food and Drug Administration (FDA) has approved Ebglyss™ (lebrikizumab-lbkz) for the treatment of adult and pediatric ...

The canine atopic dermatitis treatment market is set to experience notable growth, with an expected increase from USD ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688; "Zai Lab") today announced that data from a preclinical study of ZL-1503, the ...

A new single-dose autoinjector presentation of Adbry is now available for use in the treatment of moderate to severe atopic dermatitis.

Eczema is a chronic skin condition that shares similarities with autoimmune skin conditions, but it’s not an autoimmune ...